DAYANG BIOTECH(SZ:003017)2022-11-19 03:06Group 1: Company Performance and Financials - The company reported a projected profit growth of 10%-30% for the year based on previous year's performance [3] - The capital reserve for 2021 was 564 million, indicating potential for capital increase [2] - The company is actively repurchasing shares as part of its stock incentive or employee stock ownership plan [2] Group 2: Production Capacity and Projects - The first phase of the Fujian subsidiary has an annual production capacity of 1,500 tons for 2-chloro-6-fluorobenzaldehyde and other aromatic hydrocarbon products [2] - The second phase of the trifluoroacetyl series includes 3,800 tons of trifluoroethyl acetate and other products [2] - The trifluoroacetyl series products are expected to start production in September 2023 [2] Group 3: Market and Raw Material Impact - The company is adjusting the sales prices of end products to mitigate the impact of rising raw material costs [3] - The company is monitoring the market demand for its products and adjusting production accordingly [5] - The pandemic has not significantly affected the procurement and transportation of potassium chloride raw materials [4] Group 4: Project Development and Regulatory Compliance - The trifluoroacetyl project is currently in the preparatory approval stage [4] - The company is addressing technical issues related to the production capacity utilization rate, which is approximately 60% [4] - The company is committed to complying with safety and environmental regulations in optimizing its production processes [4]